Record EBITDA and Cash Flow
Achieved record EBITDA of $256 million, expanding EBITDA margin to 34% in the quarter. Generated record cash flow of $194 million with a conversion rate to net income of 128%.
Fiscal Year 2025 Financial Performance
Record sales of $2.8 billion, up 4% from last year, and record adjusted earnings per share of $10.24, exceeding the midpoint of initial full-year guidance.
Successful Integration of Atrion Medical
The integration of Atrion Medical was successful and contributed to sales and EPS growth in its first year.
Strong Free Cash Flow Generation
Full-year free cash flow conversion of 136% of net income, enabling $300 million share repurchase, increased dividends, and reduced net debt.
Medical and Fluid Solutions Segment Growth
Sales increased by 10%, with organic sales volume up 7%, EBITDA margin improved from 36% to 40%.